Genmab (GMAB) denied Saturday allegations of misappropriating trade secrets related to the use of disaccharides in antibody-drug conjugates in a lawsuit filed by AbbVie (ABBV).
The company said it would defend itself against AbbVie's complaint, which also named ProfoundBio and former AbbVie employees as defendants. Genmab acquired ProfoundBio in May 2024.
AbbVie is seeking damages and injunctions but is not pursuing patent enforcement, Genmab said.
Genmab said its collaboration with AbbVie on the epcoritamab program will not be affected by the lawsuit.
AbbVie did not immediately respond to MT Newswires' request for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments